Medovex seeks $80 million IPO

Subscribe via: RSS

Financing, Medical device

Posted on 20 December 2014

Medovex has priced its initial public offering of 1,391,305 units, each unit consisting of one share of common stock and one Series A Warrant, at a price to the public of $5.75 per unit.

The units are expected to begin trading on The NASDAQ Capital Market on December 19, 2014 under the ticker symbol "MDVXU."

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

The closing of the offering is expected to occur on December 24, 2014, subject to customary closing conditions.

Medovex intends to use the net proceeds it receives from the offering to fund its clinical trials and product development, related regulatory expenses, and general administrative expenses, and for general working capital purposes.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog